The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Ibrutinib treatment improves T cell number and function in CLL patients
Open accessAbstract
BACKGROUND: Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton's tyrosine kinase (BTK) and IL-2-inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS: Peripheral blood mononuclear cells from chronic lymphocytic leukemia (CLL) patients on clinical trials of ibrutinib (BTK/ITK inhibitor; n = 19) or acalabrutinib (selective BTK inhibitor; n = 13) were collected serially. T cell phenotype, immune function, and CLL cell immunosuppressive capacity were evaluated. RESULTS: Ibrutinib markedly increased CD4+ and CD8+ T cell numbers in CLL patients. This effect was more prominent in effector/effector memory subsets and was not observed with acalabrutinib. Ex vivo studies demonstrated that this may be due to diminished activation-induced cell death through ITK inhibition. PD-1 and CTLA-4 expression was significantly markedly reduced in T cells by both agents. While the number of Treg cells remained unchanged, the ratio of these to conventional CD4+ T cells was reduced with ibrutinib, but not acalabrutinib. Both agents reduced expression of the immunosuppressive molecules CD200 and BTLA as well as IL-10 production by CLL cells. CONCLUSIONS: Ibrutinib treatment increased the in vivo persistence of activated T cells, decreased the Treg/CD4+ T cell ratio, and diminished the immune-suppressive properties of CLL cells through BTK-dependent and -independent mechanisms. These features provide a strong rationale for combination immunotherapy approaches with ibrutinib in CLL and other cancers. TRIAL REGISTRATION: ClinicalTrials.gov NCT01589302 and NCT02029443. Samples described here were collected per OSU-0025. FUNDING: The National Cancer Institute.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Differentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · cited 1×
“This differs from healthy donors, who usually have less than approximately 1%–2% of TSCM cells among the naive T cell gate (34).”
BackgroundSelf-citationAcalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Harrington, B., O’Brien, S., Jones, J. A., Schuh, A., Devereux, S., Chaves, J., Wierda, W. G., Awan, F. T., Brown, J. R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509981 · Cited by 897
Self-citationDubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Self-citationDefective B cell development and function in Btk-deficient mice
Khan, W. N., Alt, F. W., Gerstein, R. M., Malynn, B. A., Larsson, I., Rathbun, G., Davidson, L., Müller, S., Kantor, A. B., Herzenberg, L. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90114-0 · Cited by 726
Pakker, N. G., Notermans, D. W., De Boer, R. J., Roos, M. T. L., Wolf, F. D., Hill, A., Leonard, J. M., Danner, S. A., Miedema, F., & Schellekens, P. T. A. (1998) · Nature Medicine · doi:10.1038/nm0298-208 · Cited by 701
Activation‐induced cell death in T cells
Green, D. R., Droin, N., & Pinkoski, M. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00051.x · Cited by 647
Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood · doi:10.1182/blood-2011-10-386417 · Cited by 640
Riches, J. C., Davies, J. K., McClanahan, F., Fatah, R., Iqbal, S., Agrawal, S., Ramsay, A. G., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-09-457531 · Cited by 529
Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
Kalos, M., & June, C. H. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.002 · Cited by 486
Self-citationBruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., Gorjestani, S., Liudahl, S. M., Truitt, M., Olson, P., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0827 · Cited by 486
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Fraietta, J. A., Beckwith, K. A., Patel, P. R., Ruella, M., Zheng, Z., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., McGettigan, S. E., Cook, D. R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679134 · Cited by 474
Self-citationRobbins, P. F., Dudley, M. E., Wunderlich, J., El-Gamil, M., Li, Y. F., Zhou, J., Huang, J., Powell, D. J., & Rosenberg, S. A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7125 · Cited by 463
Sagiv-Barfi, I., Kohrt, H. E. K., Czerwinski, D. K., Ng, P. P., Chang, B. Y., & Levy, R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500712112 · Cited by 444
Perturbation of the normal immune system in patients with CLL
Forconi, F., & Moss, P. (2015) · Blood · doi:10.1182/blood-2015-03-567388 · Cited by 385
Nonredundant Roles for B Cell-Derived IL-10 in Immune Counter-Regulation
Madan, R., Demircik, F., Surianarayanan, S., Allen, J. L., Divanovic, S., Trompette, A., Yogev, N., Gu, Y., Khodoun, M., Hildeman, D., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900185 · Cited by 295
B10 Cells: A Functionally Defined Regulatory B Cell Subset
Tedder, T. F. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401329 · Cited by 283
Adoptive Immunotherapy for Cancer or Viruses
Maus, M. V., Fraietta, J. A., Levine, B. L., Kalos, M., Zhao, Y., & June, C. H. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120136 · Cited by 264
Self-citationKavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256
Jitschin, R., Braun, M., Büttner, M., Dettmer-Wilde, K., Bricks, J., Berger, J., Eckart, M. J., Krause, S. W., Oefner, P. J., Le Blanc, K., et al. (2014) · Blood · doi:10.1182/blood-2013-12-546416 · Cited by 251
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
Brusa, D., Serra, S., Coscia, M., Rossi, D., D'Arena, G., Laurenti, L., Jaksic, O., Fedele, G., Inghirami, G., Gaidano, G., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.077537 · Cited by 222
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease
Dubovsky, J. A., Flynn, R., Du, J., Harrington, B. K., Zhong, Y., Kaffenberger, B., Yang, C., Towns, W. H., Lehman, A., Johnson, A. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75328 · Cited by 203
Self-citationNiemann, C. U., Herman, S. E. M., Maric, I., Gomez-Rodriguez, J., Biancotto, A., Chang, B. Y., Martyr, S., Stetler-Stevenson, M., Yuan, C. M., Calvo, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1965 · Cited by 201
Self-citationRegulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice
Horikawa, M., Minard-Colin, V., Matsushita, T., & Tedder, T. F. (2011) · Journal of Clinical Investigation · doi:10.1172/jci59266 · Cited by 191
Ibrutinib: A First in Class Covalent Inhibitor of Bruton's Tyrosine Kinase
Davids, M. S., & Brown, J. R. (2014) · Future Oncology · doi:10.2217/fon.14.51 · Cited by 189
Chen, S.-S., Chang, B. Y., Chang, S., Tong, T., Ham, S., Sherry, B., Burger, J. A., Rai, K. R., & Chiorazzi, N. (2016) · Leukemia · doi:10.1038/leu.2015.316 · Cited by 188
Ruella, M., Kenderian, S. S., Shestova, O., Fraietta, J. A., Qayyum, S., Zhang, Q., Maus, M. V., Liu, X., Nunez-Cruz, S., Klichinsky, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1527 · Cited by 188
Self-citationGomez-Rodriguez, J., Wohlfert, E. A., Handon, R., Meylan, F., Wu, J. Z., Anderson, S. M., Kirby, M. R., Belkaid, Y., & Schwartzberg, P. L. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131459 · Cited by 180
DiLillo, D. J., Weinberg, J. B., Yoshizaki, A., Horikawa, M., Bryant, J. M., Iwata, Y., Matsushita, T., Matta, K. M., Chen, Y., Venturi, G. M., et al. (2013) · Leukemia · doi:10.1038/leu.2012.165 · Cited by 175
Ross, M. E., & Caligiuri, M. A. (1997) · Blood · doi:10.1182/blood.v89.3.910 · Cited by 153
Self-citationAugmented Induction of CD4+CD25+ Treg using Monoclonal Antibodies to CD200R
Gorczynski, R. M., Lee, L., & Boudakov, I. (2005) · Transplantation · doi:10.1097/01.tp.0000152118.51622.f9 · Cited by 130
Selective Itk Inhibitors Block T-Cell Activation and Murine Lung Inflammation
Lin, T.-A., McIntyre, K. W., Das, J., Liu, C., O'Day, K., Penhallow, B. A., Hung, C.-Y., Whitney, G. S., Shuster, D. J., Yang, X.-X., et al. (2004) · Biochemistry · doi:10.1021/bi049428r · Cited by 113
Understanding the Immunodeficiency in Chronic Lymphocytic Leukemia
Riches, J. C., & Gribben, J. G. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.01.003 · Cited by 105
Bruton’s Tyrosine Kinase Is Required for TLR-Induced IL-10 Production
Schmidt, N. W., Thieu, V. T., Mann, B. A., Ahyi, A.-N. N., & Kaplan, M. H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.10.7203 · Cited by 91
Differential Regulation of Human NK Cell-Mediated Cytotoxicity by the Tyrosine Kinase Itk
Khurana, D., Arneson, L. N., Schoon, R. A., Dick, C. J., & Leibson, P. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.6.3575 · Cited by 89
Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade
Pallasch, C. P., Ulbrich, S., Brinker, R., Hallek, M. J., Uger, R. A., & Wendtner, C. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.08.021 · Cited by 89
Sagiv-Barfi, I., Kohrt, H. E. K., Burckhardt, L., Czerwinski, D. K., & Levy, R. (2015) · Blood · doi:10.1182/blood-2014-08-593137 · Cited by 87
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
Strati, P., Keating, M. J., Wierda, W. G., et al. (2013) · Blood · doi:10.1182/blood-2013-04-495341 · Cited by 79
Jain, P., Javdan, M., Feger, F., Chiu, P., Sison, C., Damle, R. N., Bhuiya, T., Şen, F., Abruzzo, L. V., Burger, J. A., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.047316 · Cited by 75
Miller, A. T., & Berg, L. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2163 · Cited by 74
Tyrosine Kinase Btk Is Required for NK Cell Activation
Bao, Y., Zheng, J. H., Han, C., Jin, J., Han, H., Liu, Y., Lau, Y., Tu, W., & Cao, X. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.372425 · Cited by 73
Jadidi‐Niaragh, F., Ghalamfarsa, G., Memarian, A., Asgarian‐Omran, H., Razavi, S. M., Sarrafnejad, A., & Shokri, F. (2012) · Tumor Biology · doi:10.1007/s13277-012-0628-4 · Cited by 66
Kenny, E. F., Quinn, S. R., Doyle, S., Vink, P. M., van Eenennaam, H., & O'Neill, L. A. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074103 · Cited by 66
Th17/IL-17A Might Play a Protective Role in Chronic Lymphocytic Leukemia Immunity
Hus, I., Bojarska-Junak, A. A., Chocholska, S., Tomczak, W., Woś, J., Dmoszyńska, A., & Roliński, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078091 · Cited by 61
Itk Negatively Regulates Induction of T Cell Proliferation by CD28 Costimulation
Liao, X. C., Fournier, S., Killeen, N. P., Weiss, A., Allison, J. P., & Littman, D. R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.2.221 · Cited by 59
Synergistic B Cell Activation by CD40 and the B Cell Antigen Receptor
Haxhinasto, S. A., & Bishop, G. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310628200 · Cited by 51
Memarian, A., Nourizadeh, M., Masoumi, F., Tabrizi, M. H., Emami, A. H., Alimoghaddam, K., Hadjati, J., Mirahmadian, M., & Jeddi‐Tehrani, M. (2012) · Tumor Biology · doi:10.1007/s13277-012-0578-x · Cited by 51
Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells
Natarajan, G. K., Terrazas, C. A., Oghumu, S., Varikuti, S., Dubovsky, J. A., Byrd, J. C., & Satoskar, A. R. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1057385 · Cited by 47
Self-citationTh17 Cells Undergo Fas-Mediated Activation-Induced Cell Death Independent of IFN-γ
Zhang, Y., Xu, G., Zhang, L., Roberts, A. I., & Shi, Y. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.190 · Cited by 45
Sun, Y., Peng, I., Webster, J. D., Suto, E., Lesch, J., Wu, X., Senger, K., Francis, G., Barrett, K., Collier, J. L., et al. (2015) · Science Signaling · doi:10.1126/scisignal.aab0949 · Cited by 43
Bruton's Tyrosine Kinase is Activated upon CD40 Stimulation in Human B Lymphocytes
Brunner, C. (2002) · Immunobiology · doi:10.1078/0171-2985-00192 · Cited by 25
Disruption of T Cell Suppression in Chronic Lymphocytic Leukemia by CD200 Blockade.
Pallasch, C. P., Ulbrich, S., Brinker, R., Uger, R. A., Hallek, M. J., & Wendtner, C. (2008) · Blood · doi:10.1182/blood.v112.11.2072.2072 · Cited by 23
Stubborn Tregs limit T-cell therapy
Klebanoff, C. A., & Gattinoni, L. (2012) · Blood · doi:10.1182/blood-2012-08-445239 · Cited by 2
Cited by
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
Applications of single-cell sequencing in cancer research: progress and perspectives
Lei, Y., Tang, R., Xu, J., Wang, W., Zhang, B., Liu, J., Yu, X., & Shi, S. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01105-2 · Cited by 592
Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment
Hallek, M. (2019) · American Journal of Hematology · doi:10.1002/ajh.25595 · Cited by 504
The Emerging Landscape of Immune Cell Therapies
Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 446
Self-citationKinase inhibition in autoimmunity and inflammation
Zarrin, A. A., Bao, K., Lupardus, P., & Vucic, D. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0082-8 · Cited by 431
Metadata
- Authors
- Long, M., Beckwith, K., Do, P., Mundy, B. L., Gordon, A., Lehman, A. M., Maddocks, K. J., Cheney, C., Jones, J. A., Flynn, J. M., Andritsos, L. A., Awan, F., Fraietta, J. A., June, C. H., Maus, M. V., Woyach, J. A., Caligiuri, M. A., Johnson, A. J., Muthusamy, N., & Byrd, J. C.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-07-17
- Volume
- 127
- Issue
- 8
- Pages
- 3052-3064
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2734526350
- Cited by
- 388
- References
- 54
- FWCI
- 17.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.